Our purpose is to develop breakthrough bispecific antibody therapies that can safely harness the immune system to fight cancer.

Our dedicated team of experienced scientists, physicians and professionals are passionate about building a pipeline of disruptive and differentiated bispecific antibody products tailored to the needs of the patient.

Patients first

Our primary focus is on patients and we always have their needs at the forefront of our consideration. Treating cancer patients is a balance of providing highly effective treatments with therapies that have the fewest possible side effects. The drive to push innovation to achieve this balance is at the heart of NovalGen's discoveries.

People focus

Our people are our greatest asset. At NovalGen we understand that to be able to develop groundbreaking innovations we need a dedicated entrepreneurial, expert, team who are passionate about our mission. We work collaboratively as a cross functional team to find innovative solutions which allow us to make rapid progress.

Driven by innovation

Innovation is at our core and is our passion. Our focus is on treatments for cancer using our breakthrough biological technologies in bispecific antibodies. This class of drugs address many of the limitations of current treatments and consequently are emerging as a rapidly growing class of therapeutics.

More in this section

Our team

Meet our team

Our team

Our history

Headquartered in London, UK, NovalGen was formed in 2019. The company is based on proprietary innovations from UCL, London UK.

Read more